Expertise in
22
conditions

Dr. Murali M. Chintagumpala

Hematology | Oncology
Baylor College Of Medicine
6701 Fannin St, 
Houston, TX 
Accepting New Patients
Expertise in
22
conditions
Baylor College Of Medicine
6701 Fannin St, 
Houston, TX 

Overview

Murali Chintagumpala is a Hematologist and an Oncologist practicing medicine in Houston, Texas.

Dr. Chintagumpala is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Tumor, and Nephrectomy.

He is actively involved in clinical research, co-authoring 172 peer reviewed articles and participating in 7 clinical trials. Dr. Chintagumpala is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Baylor College of Medicine
6701 Fannin St, Houston, TX 77030

Additional Areas of Focus

Dr. Chintagumpala has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine
Study Phase: Phase 2
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma
Enrollment Status: Completed
Publish Date: October 13, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy
A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

172 Total Publications

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 31, 2026
Similar Doctors
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.1 miles away)
713-792-7040
Languages Spoken:
English
See accepted insurances

William Wierda is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Wierda is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
12
conditions
Dr. Carl E. Allen
Hematology | Oncology
Expertise in
12
conditions
Dr. Carl E. Allen
Hematology | Oncology
Referral may be required

Office

1102 Bates Ave Ste 750, 
Houston, TX 
 (0.1 miles away)
832-824-4312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Allen is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Allen is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant. Dr. Allen is currently accepting new patients.

Expertise in
8
conditions
Dr. Olive S. Eckstein
Hematology | Oncology
Expertise in
8
conditions
Dr. Olive S. Eckstein
Hematology | Oncology
Referral may be required

Baylor College Of Medicine

6701 Fannin St, 
Houston, TX 
 (0.1 miles away)
832-822-4242
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Olive Eckstein is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Eckstein is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Hemophagocytic Lymphohistiocytosis. Dr. Eckstein is currently accepting new patients.

Frequently Asked Questions about Dr. Murali M. Chintagumpala

How do I make an appointment with Dr. Murali M. Chintagumpala?

You can book an appointment with Dr. Murali M. Chintagumpala by calling their office at 832-822-4242. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Murali M. Chintagumpala a top-rated expert for Medulloblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Murali M. Chintagumpala is classified as an Elite expert for Medulloblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Murali M. Chintagumpala specialize in?

While Dr. Murali M. Chintagumpala is a Hematology, they have specific expertise in Medulloblastoma, Gliomatosis Cerebri, and Brain Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Murali M. Chintagumpala participate in research or clinical trials?

Yes. Dr. Murali M. Chintagumpala has published 172 articles and abstracts on conditions like Medulloblastoma. You can view a list of Dr. Murali M. Chintagumpala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Murali M. Chintagumpala accept my insurance?

Dr. Murali M. Chintagumpala accepts most major insurance plans, including Blue Cross Blue Shield and Community Health Choice. We recommend calling the office directly at 832-822-4242 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chintagumpala's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 13 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile